JP6219016B2 - トレプロスチニル一水和物 - Google Patents
トレプロスチニル一水和物 Download PDFInfo
- Publication number
- JP6219016B2 JP6219016B2 JP2011508505A JP2011508505A JP6219016B2 JP 6219016 B2 JP6219016 B2 JP 6219016B2 JP 2011508505 A JP2011508505 A JP 2011508505A JP 2011508505 A JP2011508505 A JP 2011508505A JP 6219016 B2 JP6219016 B2 JP 6219016B2
- Authority
- JP
- Japan
- Prior art keywords
- treprostinil
- monohydrate
- solid
- anhydrous
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/487—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/14—Benz[f]indenes; Hydrogenated benz[f]indenes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
[0001]本出願は2008年5月8日に出願された米国仮出願第61/051,509号に基づく優先権を主張し、その全体を参照として本明細書に援用する。
[1]トレプロスチニルの一水和物。
[2]重量で少なくとも90%の純度で存在する、トレプロスチニル一水和物。
[3]結晶型の状態である、トレプロスチニル一水和物。
[4]a.固体を提供するために有機溶媒/水の組み合わせから無水またはウェットトレプロスチニルを再結晶化すること;
b.溶媒の付加的な留去が見られなくなるまで約15℃から約35℃までの温度で固体を風乾すること、
を含む、トレプロスチニル一水和物の製造方法。
[5]風乾の温度が約20℃から約30℃までである、[4]に記載の方法。
[6]有機溶媒が低級アルコール、低級ケトン、および低級エーテルからなる群から選択される、[4]に記載の方法。
[7]有機溶媒がエタノールである、[6]に記載の方法。
[8]有機溶媒/水の比が約1:1、または約1:2、または約1:3、または約1:4、または約1:5、または約2:1、または約3:1、または約4:1、または約5:1である、[4]に記載の方法。
[9]エタノール/水の比が約1:1である、[7]に記載の方法。
[10][9]に記載の方法によって製造されるトレプロスチニル一水和物。
[11]治療有効量のトレプロスチニル一水和物および薬剤的に受容可能なキャリアを含む医薬製剤。
[12]医学的状態を処置することが必要な対象に、治療有効量のトレプロスチニル一水和物を含む医薬製剤を投与することを含む、医学的状態を処置する方法であって、該医学的状態は肺高血圧症、鬱血性心不全、末梢血管疾患、重篤な間欠性跛行、免疫抑制、増殖性疾患、喘息、肺癌、肝臓癌、脳腫瘍、膵臓癌、腎臓癌、前立腺癌、乳癌、結腸癌、頭頸部癌、虚血性傷害、ニューロパシー足部潰瘍、肺線維症、間質性肺疾患、および腎臓機能不全または腎不全を引き起こす疾患または状態からなる群から選択される,前記方法。
[13]対象がヒト対象である、[12]に記載の方法
[0008]該一水和物はトレプロスチニルの他の形状より長い期間にわたり室温で安定である。
a.有機溶媒/水の組み合わせからトレプロスチニルを再結晶化し、濾過によって固体を集めること;および
b.それ以上溶媒が蒸発しなくなるまで周囲温度で固体を風乾すること。
[0040]TREPROSTINILはエタノールの50%水溶液から再結晶化された。“ウェット”な固体は濾過によって集め、それ以上溶媒が蒸発しなくなるまで周囲温度で風乾した。一水和物はこの乾燥プロセスの成果であった。
II.25℃におけるTREPROSTINILの無水物型対一水和物型の安定性
1.無水物lot#01A07002に関する安定性レポート(6ヶ月)
[0041]無水トレプロスチニルは以下の手順に従って調製された。
[0043]トレプロスチニル一水和物は以下の手順に従って調製された。
本実験では、500mgのトレプロスチニル一水和物試料はNalgene125ml、HDPEボトルに保管された。この実験で使用された実験手順は、lot D−1007−089に関して先に記載の手順と同じであった。
[0047]性状解析は以下の方法により行われた:
1.カールフィッシャー法による水分含量の測定、
2.融点、
3.HPLCアッセイ、
4.比旋光度、
5.IRスペクトロスコピー、
6.元素分析。
Claims (4)
- 乾燥した固体であり、結晶の形態である、トレプロスチニルの一水和物。
- 少なくとも90重量%の純度で存在する、請求項1に記載のトレプロスチニル一水和物。
- a.有機溶媒/水の組み合わせからトレプロスチニルを再結晶化し、濾過によって固体を集めること;
b.それ以上溶媒が蒸発しなくなるまで15℃から35℃までの温度で固体を風乾すること、
を含み、有機溶媒がエタノールであり、有機溶媒/水の比が1:1である、トレプロスチニル一水和物の製造方法。 - 風乾の温度が20℃から30℃までである、請求項3に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5150908P | 2008-05-08 | 2008-05-08 | |
US61/051,509 | 2008-05-08 | ||
PCT/US2009/002818 WO2009137066A1 (en) | 2008-05-08 | 2009-05-07 | Treprostinil monohydrate |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011519927A JP2011519927A (ja) | 2011-07-14 |
JP2011519927A5 JP2011519927A5 (ja) | 2017-09-07 |
JP6219016B2 true JP6219016B2 (ja) | 2017-10-25 |
Family
ID=41037724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011508505A Active JP6219016B2 (ja) | 2008-05-08 | 2009-05-07 | トレプロスチニル一水和物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8350079B2 (ja) |
EP (2) | EP3002274A1 (ja) |
JP (1) | JP6219016B2 (ja) |
KR (1) | KR20110010753A (ja) |
CN (1) | CN102015613B (ja) |
CA (1) | CA2723540C (ja) |
ES (1) | ES2575565T3 (ja) |
WO (1) | WO2009137066A1 (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2622471T5 (es) | 2003-05-22 | 2020-07-23 | United Therapeutics Corp | Compuestos y procedimientos para la administración de análogos de prostaciclina |
KR101898407B1 (ko) | 2007-12-17 | 2018-09-12 | 유나이티드 세러퓨틱스 코오포레이션 | 레모둘린®의 활성 성분인 트레프로스티닐의 개선된 제조 방법 |
WO2011115922A1 (en) | 2010-03-15 | 2011-09-22 | United Therapeutics Corporation | Treatment for pulmonary hypertension |
JP6046034B2 (ja) | 2010-06-03 | 2016-12-14 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニルの製造 |
US8461393B2 (en) | 2011-03-02 | 2013-06-11 | United Therapeutics Corporation | Synthesis of intermediate for treprostinil production |
CN103193626B (zh) | 2012-01-10 | 2016-05-11 | 上海天伟生物制药有限公司 | 一种前列腺素类似物的晶型及其制备方法和用途 |
CN103193627B (zh) | 2012-01-10 | 2016-04-20 | 上海天伟生物制药有限公司 | 一种前列腺素类似物的晶型及其制备方法和用途 |
KR102347340B1 (ko) * | 2013-03-14 | 2022-01-06 | 유나이티드 세러퓨틱스 코오포레이션 | 트레프로스티닐의 고체 형태 |
CN109608326A (zh) | 2013-03-15 | 2019-04-12 | 联合治疗公司 | 曲前列环素的盐 |
CN105228451B (zh) | 2013-03-25 | 2018-03-30 | 联合治疗公司 | 制备具有硫醇连接子和聚乙二醇化形式的前列环素化合物的方法 |
EP2991639A4 (en) | 2013-04-30 | 2016-11-30 | United Therapeutics Corp | PHARMACEUTICAL FORMULATIONS WITH CONTROLLED RELEASE |
JP6491203B2 (ja) | 2013-10-25 | 2019-03-27 | インスメッド インコーポレイテッド | プロスタサイクリン化合物、組成物およびその使用方法 |
WO2015192030A1 (en) | 2014-06-13 | 2015-12-17 | United Therapeutics Corporation | Treprostinil formulations |
WO2016038532A1 (en) * | 2014-09-09 | 2016-03-17 | Mylan Laboratories Limited | Amorphous treprostinil diethanolamine |
HU231186B1 (hu) * | 2014-10-08 | 2021-06-28 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | Új eljárás treprostinil és sói előállítására |
KR101890080B1 (ko) | 2014-10-20 | 2018-09-20 | 유나이티드 쎄러퓨틱스 코포레이션 | 프로스타시클린 유도체 제조를 위한 중간체의 합성 |
WO2016081658A1 (en) | 2014-11-18 | 2016-05-26 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
WO2017192993A1 (en) | 2016-05-05 | 2017-11-09 | Liquidia Technologies, Inc. | Dry powder treprostinil for the treatment of pulmonary hypertension |
EP3515430A1 (en) | 2016-09-26 | 2019-07-31 | United Therapeutics Corporation | Treprostinil prodrugs |
CA3045917A1 (en) | 2016-12-05 | 2018-06-14 | Corsair Pharma, Inc. | Dermal and transdermal administration of treprostinil and salts thereof |
EA202190552A1 (ru) | 2018-09-18 | 2021-06-18 | Эли Лилли Энд Компани | Эрбуминовая соль трепростинила |
JP7455144B2 (ja) | 2019-04-29 | 2024-03-25 | インスメッド インコーポレイテッド | トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法 |
JP7365073B2 (ja) * | 2019-05-21 | 2023-10-19 | ジァンスー フォアフロント ファーマシューティカル カンパニー,リミテッド | トレプロスチニルナトリウムの新規な結晶形および製造方法 |
AU2020337342A1 (en) | 2019-08-23 | 2022-02-24 | United Therapeutics Corporation | Treprostinil prodrugs |
US11339110B2 (en) * | 2019-12-19 | 2022-05-24 | Chirogate International Inc. | Efficient crystallization process for preparing ultrapure Treprostinil and crystal prepared therefrom |
CN115916212A (zh) | 2020-04-17 | 2023-04-04 | 联合治疗公司 | 曲前列尼尔用于治疗间质性肺病 |
CN116113415A (zh) | 2020-06-09 | 2023-05-12 | 联合治疗公司 | 曲前列尼尔的富马酰基二酮哌啶前药 |
US11447440B2 (en) | 2020-10-29 | 2022-09-20 | Chirogate International Inc. | Treprostinil monohydrate crystals and methods for preparation thereof |
WO2022132655A1 (en) | 2020-12-14 | 2022-06-23 | United Therapeutics Corporation | Methods of treating disease with treprostinil prodrugs |
EP4301372A1 (en) | 2021-03-03 | 2024-01-10 | United Therapeutics Corporation | A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp) |
WO2023154705A1 (en) | 2022-02-08 | 2023-08-17 | United Therapeutics Corporation | Treprostinil iloprost combination therapy |
US20240287105A1 (en) | 2023-01-19 | 2024-08-29 | United Therapeutics Corporation | Treprostinil analogs and related methods of making and using |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4306075A (en) * | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
GB8814438D0 (en) * | 1988-06-17 | 1988-07-20 | Wellcome Found | Compounds for use in medicine |
US5763426A (en) * | 1993-01-15 | 1998-06-09 | Leo Pharmaceutical Products Ltd. | Crystalline form of a vitamin D analogue |
JP3215338B2 (ja) * | 1995-12-15 | 2001-10-02 | 三菱化学株式会社 | アミノベンゼンスルホン酸誘導体一水和物及びその製造方法 |
IT1282733B1 (it) * | 1996-05-20 | 1998-03-31 | Flarer S A | Composizioni farmaceutiche contenenti ciclosporina ed un veicolante comprendente almeno un estere dell'acido alfa-glicerofosforico |
US6441245B1 (en) * | 1997-10-24 | 2002-08-27 | United Therapeutics Corporation | Process for stereoselective synthesis of prostacyclin derivatives |
CN1142781C (zh) | 1997-11-14 | 2004-03-24 | 联合治疗公司 | 9-脱氧-2′,9-α-亚甲基-3-氧杂-4,5,6-三去甲-3,7-(1′,3′-间亚苯基)-13,14-二氢-前列腺素F1在治疗外周血管疾病中的用途 |
US6017922A (en) * | 1998-05-18 | 2000-01-25 | U.S. Bioscience, Inc. | Thermally stable trimetrexates and processes for producing the same |
US6521212B1 (en) * | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
US6700025B2 (en) * | 2001-01-05 | 2004-03-02 | United Therapeutics Corporation | Process for stereoselective synthesis of prostacyclin derivatives |
US6803386B2 (en) * | 2002-01-16 | 2004-10-12 | United Therapeutics Corporation | Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer |
US6756117B1 (en) | 2002-12-20 | 2004-06-29 | The United States Of America As Represented By The United States Department Of Energy | Photonic polymer-blend structures and method for making |
ES2622471T5 (es) * | 2003-05-22 | 2020-07-23 | United Therapeutics Corp | Compuestos y procedimientos para la administración de análogos de prostaciclina |
KR20050024121A (ko) * | 2003-09-04 | 2005-03-10 | 동아제약주식회사 | 7-카르복시메틸옥시-3',4',5-트리메톡시 플라본.일수화물, 이의 제조방법 및 용도 |
ES2331187T3 (es) | 2003-12-16 | 2009-12-23 | United Therapeutics Corporation | Utilizacion de treprostinil para mejorar las funciones renales. |
CA2549724C (en) * | 2003-12-16 | 2014-02-11 | United Therapeutics Corporation | Use of treprostinil to treat and prevent ischemic lesions |
KR101186029B1 (ko) * | 2004-04-12 | 2012-09-27 | 유나이티드 쎄러퓨틱스 코포레이션 | 신경병증성 당뇨병성 족부 궤양을 치료하기 위한트레프로스티닐의 용도 |
US8747897B2 (en) * | 2006-04-27 | 2014-06-10 | Supernus Pharmaceuticals, Inc. | Osmotic drug delivery system |
WO2007134292A2 (en) | 2006-05-15 | 2007-11-22 | United Therapeutics Corporation | Treprostinil administration using a metered dose inhaler |
WO2008049000A2 (en) * | 2006-10-18 | 2008-04-24 | United Therapeutics Corporation | Combination therapy for pulmonary arterial hypertension |
KR20090117781A (ko) * | 2007-02-09 | 2009-11-12 | 유나이티드 세러퓨틱스 코오포레이션 | 간질성 폐질환 및 천식을 위한 트레프로스티닐 치료법 |
US20080280985A1 (en) | 2007-03-27 | 2008-11-13 | Scott Robert A D | Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes |
KR101898407B1 (ko) * | 2007-12-17 | 2018-09-12 | 유나이티드 세러퓨틱스 코오포레이션 | 레모둘린®의 활성 성분인 트레프로스티닐의 개선된 제조 방법 |
-
2009
- 2009-05-07 ES ES09743053.2T patent/ES2575565T3/es active Active
- 2009-05-07 WO PCT/US2009/002818 patent/WO2009137066A1/en active Application Filing
- 2009-05-07 CA CA2723540A patent/CA2723540C/en active Active
- 2009-05-07 KR KR1020107027068A patent/KR20110010753A/ko not_active Application Discontinuation
- 2009-05-07 CN CN2009801161262A patent/CN102015613B/zh active Active
- 2009-05-07 EP EP15190454.7A patent/EP3002274A1/en not_active Withdrawn
- 2009-05-07 EP EP09743053.2A patent/EP2300408B1/en active Active
- 2009-05-07 US US12/437,054 patent/US8350079B2/en active Active
- 2009-05-07 JP JP2011508505A patent/JP6219016B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US8350079B2 (en) | 2013-01-08 |
CA2723540A1 (en) | 2009-11-12 |
ES2575565T3 (es) | 2016-06-29 |
CN102015613B (zh) | 2013-07-31 |
CA2723540C (en) | 2016-01-05 |
JP2011519927A (ja) | 2011-07-14 |
KR20110010753A (ko) | 2011-02-07 |
EP3002274A1 (en) | 2016-04-06 |
EP2300408A1 (en) | 2011-03-30 |
WO2009137066A1 (en) | 2009-11-12 |
EP3002274A8 (en) | 2016-07-13 |
CN102015613A (zh) | 2011-04-13 |
EP2300408B1 (en) | 2016-04-13 |
US20090281189A1 (en) | 2009-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6219016B2 (ja) | トレプロスチニル一水和物 | |
JP7030093B2 (ja) | オキサチアジン様化合物を作製する方法 | |
US7446116B2 (en) | Montelukast amantadine salt | |
TWI530501B (zh) | 純化十字孢靈素之方法 | |
JP2010527996A (ja) | テノホビルジソプロキシル−ヘミフマル酸共結晶 | |
KR102317158B1 (ko) | 항미생물 화합물, 조성물, 및 그의 용도 | |
WO2016000568A1 (zh) | 一种治疗痛风的化合物 | |
US9504672B2 (en) | Compositions and methods for treating or preventing pneumovirus infection and associated diseases | |
JP2007515430A (ja) | アルコール及びケトン、及び/又はエステルの混合物である有機溶媒に塩を溶解し、そして溶媒を除去することにより非晶質アトルバスタチンへミ−カルシウムの調製方法 | |
WO2021139797A1 (zh) | 恩曲替尼晶型及其制备方法 | |
KR20150046369A (ko) | 데페라시록스 (icl670a)의 다형체 형태 | |
EP2609096A1 (en) | New tiotropium bromide crystal and its production method | |
JPH03503162A (ja) | 化学療法における毒性特性の改良 | |
WO2022233310A1 (zh) | 丹酚酸a盐水合物、其制备方法及用途 | |
EP3984993A1 (en) | Use of aminothiol compounds as cerebral nerve or heart protective agent | |
UA52661C2 (uk) | Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти | |
CN104829467A (zh) | 盐酸氨溴索二水化合物 | |
CN113831336A (zh) | 吡喹酮与阿魏酸共晶物及制备方法和其组合物与用途 | |
JP6871919B2 (ja) | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 | |
WO2020056974A1 (zh) | 一种泊沙康唑磷酸酯单胆碱盐及其制备方法和用途 | |
JP2019513151A (ja) | カンプトテシン誘導体及びその使用 | |
JPS6245846B2 (ja) | ||
CN108623629B (zh) | 一类治疗血栓相关性疾病的化合物、制备方法及其药物用途 | |
CN117756798A (zh) | 一种异丙托溴铵新晶体及其制备方法 | |
JPS60346B2 (ja) | S−(3−メチル−2−ブテニル)システインならびにその製法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120413 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131213 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140313 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140320 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140407 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140606 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140908 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140916 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140929 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150416 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150529 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20150626 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160824 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170317 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170421 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170522 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20170727 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170927 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6219016 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |